ANNUAL REPORT 2021

LUNDBECK ANNUAL REPORT 2021 = CONTENTS Products STRATEGIC BRANDS Ability Maintena 400 mg wture de anpipel 28 ilmovicure phitur Brintellix 10mg filmovertrukne tabletter vortioxetine Indtages pennet munden 28 filmovertrukne tabletter/draslene tableter RXULTI 1mg filmovertrukne tabletter/ tabletter, filmdrasjerte brexpiprazol/brekspiprazol Oral anvender Oralik vyepti (ectinazumab jnr) injection 100 mg/ml F E Abilify Maintena® (aripiprazole once-monthly) Monthly intramuscular injection indicated for the treatment of schizophrenia. Lundbeck markets Abilify MaintenaⓇ in the U.S. in collaboration with Otsuka Pharmaceutical Co., Ltd. and in Europe and International Markets either alone or in collaboration with Otsuka Pharmaceutical Co., Ltd. First launched in the U.S. in 2013, hereafter launched in close to 40 countries. Brintellix /TrintellixⓇ (vortioxetine) Indicated for the treatment of Major Depressive Disorder (MDD). Lundbeck markets Brintellix®/Trintellix® in Europe and International Markets. In the U.S., Takeda Pharmaceutical Company Limited is our co-promotion partner. Launched in the first markets in 2014 and now available in approximately 60 countries. Rexulti /Rxulti® (brexpiprazole) Indicated for adjunctive therapy for the treatment of adults with Major Depressive Disorder (MDD) and as a treatment for adults with schizophrenia. Launched in the U.S. in 2015 in collaboration with Otsuka Pharmaceu- tical Co., Ltd. hereafter in a number of other countries. Vyepti® (eptizumab) Indicated for the preventive treatment of migraine in adults. Approved by the U.S. FDA in early 2020. In 2021, Vyepti was approved in Canada, Switzerland, the U.A.E., Kuwait, and Australia. End of 2021, VyeptiⓇ was also recommended for approval in the EU by the Committee for Medicinal Products for Human Use (CHMP). REVENUE (DKKm) 2,420 % OF TOTAL REVENUE 15% ▲7% REVENUE (DKKm) 3,526 % OF TOTAL REVENUE 22% ▲ 14% REVENUE (DKKm) 2,849 % OF TOTAL REVENUE 17% 19% REVENUE (DKKm) 492 429% % OF TOTAL REVENUE 3% 30/111

View entire presentation